An informational resource for healthcare professionals interested in stroke reduction, venous protection, and vascular protection. Stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events through the many resources found in the tabs listed here.
Educational resources about reducing stroke by understanding the underlying thrombotic risk in patients with or without atrial fibrillation.
Educational resources about the underlying thrombotic risk of major adverse cardiac events in patients with vascular diseases such as Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Heart Failure.
Pulmonary embolism (PE) is responsible for 300,000 US deaths each year. Initial PE-related hospitalization costs were estimated at $13,300-$31,000 annually.
Critical limb ischemia (CLI) is prevalent in approximatley 1.3% of the adult population, and a specific association between diabetes and CLI has been long established. Comorbid diabetes has been estimated to be prevalent in up to 30% of the CLI population.
Peripheral artery disease (PAD) is manifested over a continuum of severity, with severe PAD patients at greater risk for comorbid coronary artery disease, diabetes, and renal disease and related complications. Increased number of comorbidities contributes to greater healthcare resource utilization (HRU) and healthcare costs (HC). An aging population, with increased prevalence of severe PAD and associated comorbidities, may increase these costs.
Various risk stratification methods exist for patients with pulmonary embolism (PE). Use the simplified Pulmonary Embolism Severity Index (sPESI) as a risk stratification method to understand the PE population within the Veterans Health Administration (VHA).
Heart failure (HF) prevalence has increased progressively over the past several decades, primarily owing to a reduction in myocardial infarction (MI) mortality and the general US population's prolonged lifespan. Over 5.7 million people are currently living with HF in the United States. Among adults aged =40 years, it is estimated that =1 in 5 will be diagnosed with HF during their lifetime.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.